Predicting the treatment outcome of nivolumab in recurrent or metastatic head and neck squamous cell carcinoma: prognostic value of combined performance status and modified Glasgow prognostic score

Background: Aim of the study was to compare the response of altered fractionation schedule with concurrent chemo-radiation in patients with primary and the nodal disease.Methods: Total of 40 patients (20 in each arm) with stage 1- 4 squamous cell carcinoma of the head and neck with a performance status of 0-2 (ECOG) were included in the study. Arm A was altered fractionation schedule where in patients received 6 fractions per week to a total dose of 6600 cGy in 33 fractions. In Arm B, patients received conventional radiotherapy with concurrent chemotherapy three weekly Inj. of cisplatin (100 mg/m2). Patients were evaluated for acute toxicity every week using the Acute Radiation Morbidity Scoring Criteria. The response was assessed after 6 weeks and 12 weeks post treatment using the RECIST criteria. Data was statistically analyzed.Results: Seventeen patients in Arm A and 18 patients in Arm B completed the treatment. At the end of three months, In Arm A, 7 patients had complete response and in Arm B, 9 patients had complete response of the primary (p>0.05). When the complete nodal response was compared in both the arms, there was no difference (2 vs 4 in Arm A vs Arm B resp.). But there were more partial nodal responders in Arm B (p = 0.016). The acute toxicities were comparable in both the arms.Conclusions: Altered fraction radiotherapy can be used in early lesions with minimal nodal burden but with locally advanced disease or large nodal burden addition of chemotherapy should not be avoided.

Download Full-text

Prognostic value of lymph node ratio in head and neck squamous cell carcinoma

Head & Neck ◽

10.1002/hed.25080 ◽

2018 ◽

Vol 40 (5) ◽

pp. 1082-1090 ◽

Cited By ~ 21

Author(s):

Yoav P. Talmi ◽

Robert P. Takes ◽

Eran E. Alon ◽

Iain J. Nixon ◽

Fernando López ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Lymph Node ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Prognostic Value ◽

Lymph Node Ratio ◽

Neck Squamous Cell Carcinoma ◽

Node Ratio

Download Full-text

Real-world effectiveness of Glasgow prognostic score and tumor biomarkers in predicting post-relapse survival in patients with recurrent cervical cancer after minimally invasive surgery

10.21203/rs.3.rs-15854/v1 ◽

2020 ◽

Author(s):

Junhui Guo ◽

Yuanyuan Wang ◽

Xinxin Wang ◽

Shengli Zhou ◽

Peimin Liu

Keyword(s):

Cervical Cancer ◽

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Clinical Data ◽

Squamous Cell ◽

Real World ◽

Prognostic Score ◽

Glasgow Prognostic Score ◽

Tumor Biomarkers ◽

Recurrent Cervical Cancer

Abstract Background Cervical cancer ranks the third most common malignancy of women worldwide, and recurrence of cervical cancer treatment is the major concern. Carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), squamous cell carcinoma antigen (SCCA) and Glasgow Prognostic Score (GPS) were potential prognostic indicator for cervical cancer. However, none of these markers have been evaluated to predict post-relapse survival in recurrent cervical cancer after treatment based on real-world clinical data. Aim To evaluate biomarkers CEA, CA125, SCCA and Glasgow Prognostic Score (GPS) in predicting post-relapse survival in recurrent cervical cancer after treatment based on real-world clinical data. Results Among the 1607 patients, the majority of patients (75.5%) were non-smokers, and the majority of histologic type (68.3%) was squamous cell carcinoma. Except CEA, there were significant difference between different GPS groups in these markers. Areas under the curves (AUC) for GPS, CEA, CA125 and SCCA were 0.632, 0.617, 0.641 and 0.628, respectively. All clinicopathologic characteristics were significantly correlated with CA125. Higher levels of biomarkers and GPS had lower survival and GPS=2 and SCCA was an independent prognostic factor for survival (P=0.008 and P=0.010, respectively). Conclusions In real-world settings, GPS and tumor biomarkers, especially SCCA to independently predict post-recurrence survival in patients with recurrent cervical cancer.

Download Full-text